Cancer Research Club March 2020
ELISA Genie is delighted to announce the date of our next Cancer Research Club which will be taking place on the 31st of March at TTMI, Trinity College Dublin. This event will focus on the role of the mucosal immunity & genetic pathology of the colon.
Genetic Pathology & Mucosal Immunity
Date: 31/03/2020
Time: 1:30 pm - 5 pm
Trinity Translational Medicine Institute, St James's Hospital
Organizer:
Prof. Jacintha O'Sullivan
Trinity College Dublin
Guest Speakers
Prof. Ian Frayling
The Royal College of Pathologists
Ian qualified in Clinical Medicine at Cambridge. Up until his recent retirement from NHS Wales he was the only Genetic Pathologist in NHS service, but he hasn’t retired from medicine, yet! He is now Honorary Consulting Genetic Pathologist to the National Centres for Colorectal Disease of the UK (at St Mark’s Hospital, London) and Ireland (at St Vincent’s Hospital, Dublin). He is also an Honorary Senior Clinical Research Fellow in the Inherited Tumour Syndromes Research Group at Cardiff University, and an Honorary Medical Adviser to Lynch Syndrome UK, as well as a member of InSiGHT Council and Honorary Treasurer of both InSiGHT and the UK Cancer Genetics Group. In 1993 Ian established gene and tumour testing for hereditary bowel cancer at St Mark’s Hospital. He now concentrates on gene variant interpretation, genotype-phenotype correlations, and mechanisms of tumour evolution. He played a major role in establishing NICE Diagnostics Guidance DG27 – that all colorectal cancers in the UK should be tested for Lynch syndrome. He is also a co-author on the hereditary cancer sections in the new 5th Edition of the World Health Organisation Classification of Tumours series. Ian has been conferred with Honorary Fellowship of the Faculty of Pathology of the Royal College of Physicians of Ireland, and is a recipient of both the Association of Clinical Pathologists Dyke Foundation Medal and the Pathological Society of Great Britain and Ireland’s Goudie Medal for his “seminal contribution to the science of pathology.”
Dr. Elizabeth Ryan
University of Limerick
Dr. Ryan is a Lecturer in Immunology in the Department of Biological Sciences. My research focuses on understanding the role of human myeloid cells in controlling inflammation. I am particularly interested in how these important immune cells might be manipulated by the local tissue environment in diseases such as Inflammatory Bowel Disease and Colorectal Cancer.
Dr. Peter Caie
University of St. Andrews
Dr. Caie is a Senior Research Fellow at the University of St Andrews and is Principal Investigator at the QUAntitative and Digital (QUAD) pathology group. His work concentrates on applying digital pathology, complex image analysis, integrative big data, multi-omics and artificial intelligence to answer clinically transferable research questions. He submitted his PhD in Digital and Quantitative Pathology at the University of Edinburgh while building a Scottish wide Quantitative and Systems Pathology collaborative group spanning both clinical and academic settings. Previously, Dr. Caie attained an M.Res in Medical biochemistry and a B.Sc in Molecular and Cellular biology, both from the University of Glasgow. Furthermore, Dr. Caie worked in the pharmaceutical industry with AstraZeneca for nine years where he developed high content biology assays for in vitro drug discovery.
Schedule:
Location:
Registration:
Recent Posts
-
Pembrolizumab Biosimilar HDBS0006: Expanding Access to PD-1 Immunotherapy
Pembrolizumab (Keytruda), a monoclonal antibody targeting programmed death-1 (PD-1), h …27th Nov 2024 -
Vorsetuzumab Biosimilar HDBS0005: Advancing CD70-Targeted Immunotherapy
Vorsetuzumab, a monoclonal antibody targeting CD70, is an investigational therapy desi …27th Nov 2024 -
Talacotuzumab Biosimilar HDBS0003: Advancing CD123-Targeted Cancer Therapy
Talacotuzumab, a humanized monoclonal antibody targeting CD123, has shown promise in t …27th Nov 2024